These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 27686171

  • 1. Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
    Gardner JA, Peterson JD, Turner SA, Soares BL, Lancor CR, Dos Santos LL, Kaur P, Ornstein DL, Tsongalis GJ, de Abreu FB.
    Am J Clin Pathol; 2016 Oct; 146(4):448-55. PubMed ID: 27686171
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 Oct; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 4. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK, Murugesan G, Cotta CV, Theil KS.
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [Abstract] [Full Text] [Related]

  • 5. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y, Fang F, Hu Y, Liu Q, Bu D, Tan M, Wu L, Zhu P.
    PLoS One; 2016 Aug; 11(4):e0154183. PubMed ID: 27111338
    [Abstract] [Full Text] [Related]

  • 6. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA.
    BMC Cancer; 2019 Jun 17; 19(1):590. PubMed ID: 31208359
    [Abstract] [Full Text] [Related]

  • 15. A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms.
    Yao QM, Zhou J, Gale RP, Li JL, Li LD, Li N, Chen SS, Ruan GR.
    Hematology; 2015 Oct 17; 20(9):517-22. PubMed ID: 25860380
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
    Trung NT, Quyen DT, Hoan NX, Giang DP, Trang TTH, Velavan TP, Bang MH, Song LH.
    BMC Med Genet; 2019 Jun 27; 20(1):115. PubMed ID: 31248375
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.